Patents by Inventor Sara Cotter

Sara Cotter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating Prader-Willi syndrome
    Patent number: 11957656
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: April 16, 2024
    Assignees: The Trustees of Columbia University in the City of New York, Levo Therapeutics, Inc.
    Inventors: Lisa Cole Burnett, Dieter Egli, Rudolph L Leibel, Sara Cotter
  • METHODS OF TREATING PRADER-WILLI SYNDROME
    Publication number: 20210113521
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Application
    Filed: October 26, 2020
    Publication date: April 22, 2021
    Inventors: Lisa Cole BURNETT, Dieter EGLI, Rudolph L. LEIBEL, Sara COTTER
  • Methods of treating prader-willi syndrome with carbetocin
    Patent number: 10967040
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: April 6, 2021
    Assignee: Levo Therapeutics, Inc.
    Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
  • Methods of treating Prader-Willi syndrome
    Patent number: 10842775
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 24, 2020
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, LEVO THERAPEUTICS, INC.
    Inventors: Lisa Cole Burnett, Dieter Egli, Rudolph L. Leibel, Sara Cotter
  • STABLE INTRANASAL FORMULATIONS OF CARBETOCIN
    Publication number: 20200353029
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Applicant: Levo Therapeutics, Inc.
    Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
  • METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
    Publication number: 20200016164
    Abstract: This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.
    Type: Application
    Filed: February 15, 2019
    Publication date: January 16, 2020
    Inventor: Sara Cotter
  • METHODS OF TREATING PRADER-WILLI SYNDROME
    Publication number: 20190298686
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Application
    Filed: June 2, 2017
    Publication date: October 3, 2019
    Applicants: The Trustees of Columbia University in the City of New York, Levo Therapeutics, Incs, Inc.
    Inventors: Lisa Cole BURNETT, Dieter EGLI, Rudolph L. LEIBEL, Sara COTTER
  • METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
    Publication number: 20160228449
    Abstract: This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.
    Type: Application
    Filed: September 10, 2015
    Publication date: August 11, 2016
    Inventor: Sara Cotter